Large-Joint Reconstructive Implants – Market Insights – United States

COVID-19–related delays to hip and knee replacement procedures negatively impacted the US large-joint reconstructive implant market in 2020 and into 2021; however, the market saw strong year-over-year growth in 2021 overall, largely attributable to the rescheduling of procedures that were deferred in 2020. Following the short-term impact of the pandemic, the market will see long-term growth, driven by the uptake of novel technologies such as patient-conforming and 3-D printed implants, smart implants, robotic- and navigation-assisted surgeries, and minimally invasive techniques, although downward pricing pressures driven by bundled payment initiatives such as the CJR and BPCI Advanced models, growing outpatient joint replacement volumes, and the increasing influence of GPOs will limit overall revenue potential to some degree.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for large-joint reconstructive implants in the US across a 12-year period.

The impact of the COVID-19 pandemic on markets for devices used in elective procedures, including hip and knee reconstructive implants, continued in 2021.

How were procedure volumes in different segments of the market affected by the crisis?

How quickly have procedure volumes recovered?

How have competitors adapted to the COVID-19 pandemic?

When will each segment of the market return to levels seen prior to the pandemic?

The COVID-19 pandemic has caused ongoing site-of-service shifts in the large-joint reconstructive implant to accelerate and is driving innovation to improve OR efficiency and reduce cost.

How has the COVID-19 pandemic affected the shift away from inpatient setting?

Which procedures are seeing an increasing shift to outpatient settings?

How will differing reimbursement rates in hospital versus non-hospital settings affect product choices and treatment approaches?

How are companies tailoring their strategies to cater to the needs of hospital outpatient departments and ASCs?

Which products are being developed to enable shorter surgery and recovery times in outpatient settings?

Technological innovation will have a significant impact on the US large-joint reconstruction market.

What has driven the recent innovations in robotics from major competitors in the large-joint reconstructive implant space?

How are companies changing their product mix to meet the trends surrounding robotic assistance, navigation technologies, and personalized implants?

How is the adoption of robotics and related ecosystems impacting the market and practice within the OR? 

How important is clinical data to the adoption of newer materials and technologies in this space, given the large number of recalls and lawsuits against device manufacturers?

How are innovative technologies and value-based solutions affecting market share shifts?

Bundled payment models such as the CJR and BPCI Advanced models will heavily influence the large-joint reconstructive implant market in the US.

How do the CJR and BPCI Advanced models differ from each other and what impact do they have on the large-joint reconstructive implant market?

How will the payment models impact the ongoing shift towards hospital outpatient and ASCs?

How will physician treatment practices change in response to bundled payment models?

How will product mix, procedure volumes, and ASPs be affected by bundled payment models?

What strategies are companies employing to succeed with the expansion of these models?

As the market shifts toward value-based incentives, healthcare providers and orthopedic manufacturers are adopting new strategies to improve patient outcomes based on total episodes of care.

What are the current purchasing priorities of healthcare facilities?

How are healthcare facilities adding value to preoperative and postoperative care?

What strategies and added services are orthopedic manufacturers adopting in response to shifting hospital demands?